Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2015

View Archived Issues

FDA provides guidance on clinical trial requirements for Rexista

LEO Pharma and arGEN-X form partnership to develop antibodies for inflammatory skin disorders

Celsion's TheraSilence technology platform delivers RNA to lungs in nonhuman primates

Medipure signs memorandum of understanding with University of British Columbia scientists

MabSpace collaborates with Genor Biopharma on antibody discovery and development

Consortium to acquire Ambrx

Eureka Therapeutics and Boehringer Ingelheim partner on antibody discovery in cancer

Wockhardt's WCK-4873 granted QIDP designation

New data further support use of emricasan for the treatment of liver diseases

Endothelial cells overexpressing IL-8 receptors improve experimental restenosis, acute kidney injury

Lipo-MERIT: a novel tetravalent RNA cancer vaccine

Chugai files NDA in Japan for psoriasis therapy M-8010

CHMP recommends approval of Simponi for non-radiographic axial spondyloarthritis

CFZ-533 shows promising data as an immunomodulating agent in transplant rejection

Low SA2 expression correlates with unfavorable outcome in breast cancer

GSK files Japanese NDA for mepolizumab in severe eosinophilic asthma

Daewoong Pharmaceutical patents novel antifungal compounds

Medivation discloses dual BTK and PI3K inhibitors

AstraZeneca patent describes NMDA antagonist prodrugs

Lilly prepares and tests TNKS inhibitors

KemPharm consults with FDA over NDA for benzhydrocodone/acetaminophen combination

Arteether amine maleate cleared to enter clinical studies in China

SB-01 approved to enter phase II study in Taiwan

Pegintron approved in Japan for postoperative adjuvant therapy in malignant melanoma

Additional indication for Laserphyrin approved in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...